ROCK2

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024
Graviton, Epilepsy, Pharmacy technician, CCM, Research, Transcranial magnetic stimulation, DS, Neuron, Vigabatrin, LGS, Psychosis, Biomarker, Element, Ligand Pharmaceuticals, Lennox–Gastaut syndrome, Patient, Acceleration, Medicine, Status epilepticus, Dravet syndrome, ROCK2, KCC2, Hemangioma, IND, Seizure, Pharmaceutical industry

In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.

Key Points: 
  • In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
  • Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
  • Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
  • Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, November 3, 2023
Graviton, MB, KCC2, Element, Research, ROCK2, IND, TMS, Seizure, Neuron, IV, Dravet syndrome, Ligand Pharmaceuticals, SAD, Lennox–Gastaut syndrome, Development, Epilepsy, In vivo magnetic resonance spectroscopy, MRS, Transcranial magnetic stimulation, EEG, Status epilepticus, Hemangioma, Pharmaceutical industry, Takeda, Ligand

The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.

Key Points: 
  • The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
  • General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
  • The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
  • Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023
Neutropenia, Hepatitis, NASH, Marketing, Sino Biopharmaceutical Limited, Liver disease, Clinical trial, Cancer, Breakthrough therapy, Respiratory system, Research, COVID, YOY, Tablet, Patient, ROCK2, CDE, Growth, HK2, Development, Center for Drug Evaluation and Research, NMPA, Idiopathic pulmonary fibrosis, Lumbar spinal stenosis, Safety, Flurbiprofen, Pharmaceutical industry, Generic drug, Fine chemical, Q2, PRC

HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period").

Key Points: 
  • HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period").
  • In the first half of 2023, two innovative products were launched to market and two biosimilar drugs received marketing approval.
  • -- Annike (Penpulimab monoclonal antibody) injection was approved in January 2023 for treating, in combination with chemotherapy, first-line locally advanced or metastatic squamous non-small cell lung cancer.
  • -- Yilishu (Efbemalenograstim alpha) injection was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs.

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, August 4, 2023
Seizure, Volunteering, Epilepsy, LGS, Partnership, Joint, MB, Schizophrenia, Lennox–Gastaut syndrome, DSM-IV codes, SAD, G&A, Brain, Dravet syndrome, Research, Pain, Development, Retirement, Myenteric plexus, ROCK2, KCC2, Therapy, IND, Safety, Pharmaceutical industry, Renewable energy, Clothing, Takeda, Graviton, DRS

Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor

Key Points: 
  • Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor
    NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.
  • “In the second quarter, we accomplished a strategic milestone for Ovid.
  • In the second quarter 2023, Ovid executed several non-routine non-operating cash expenditures.
  • Second quarter expenses included severance costs following a headcount reduction that primarily impacted roles within Ovid's G&A functions in June 2023.

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Retrieved on: 
Wednesday, June 28, 2023
Columbia University, SAB, Seizure, Postdoctoral researcher, Epilepsy, GABA, Pain disorder, Meg, Corporate Affairs, Doctor of Philosophy, MB, Rockefeller University, CSO, G&A, Research, CMO, CNS, GlaxoSmithKline Pharmaceuticals, Thought, Retirement, Syneos Health, ROCK2, Hemangioma, Vertex Pharmaceuticals, KCC2, Medical device, Pharmaceutical industry, Management

“We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • “We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Prior to joining Ovid, Dr. Zhong served in senior leadership and scientific roles at Generation Bio, Wave Life Sciences, Vertex Pharmaceuticals, and GlaxoSmithKline Pharmaceuticals.
  • Dr. Zhong will partner closely with Dr. Manoj Malhotra who is taking on an expanded role as Chief Medical Officer.
  • In addition to deepening its bench of scientific leadership, Ovid expanded the role of Meg Alexander to the position of Chief Strategy Officer.

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, May 5, 2023
Columbia University, Seizure, LGS, Human, MB, Epilepsy, Lennox–Gastaut syndrome, American Academy, Traffic barrier, Medicine, Research, Brain, Biomarker, Dravet syndrome, DS, Cholesterol 24-hydroxylase, Investigational New Drug, Animal, Patient, ROCK2, KCC2, American Academy of Neurology, IND, Safety, Pharmaceutical industry, Cryptocurrency, Takeda, Graviton

The mechanisms in this pipeline strategically position Ovid to be a leader in rare seizure-related disorders.

Key Points: 
  • The mechanisms in this pipeline strategically position Ovid to be a leader in rare seizure-related disorders.
  • Ovid will conclude its research collaboration with Columbia University by year-end 2023 and explore business development opportunities for its non-core genetic programs produced from that research initiative.
  • Financial strategy: Ovid anticipates its cash runway should fund operations into 2025 without additional funding.
  • The decrease was due to personnel cost reductions following corporate cost-cutting efforts and a headcount reduction conducted in March 2022.

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

Retrieved on: 
Monday, May 1, 2023
Seizure, Central nervous system, Therapy, MB, Epilepsy, DSM-IV codes, Hope, Traffic barrier, Brain, Spasm, Animal, ROCK2, Hemangioma, Pharmaceutical industry, Graviton

Together, the companies intend to develop ROCK2 inhibitors for the treatment of a broad range of neurological conditions marked by seizures, spasms and related symptoms.

Key Points: 
  • Together, the companies intend to develop ROCK2 inhibitors for the treatment of a broad range of neurological conditions marked by seizures, spasms and related symptoms.
  • Initial clinical development is anticipated to address cavernous malformations in the brain, for which there is strong mechanistic evidence for inhibiting ROCK2.
  • Despite this link, historically there has been limited clinical development of ROCK2 inhibitors due to challenges penetrating the blood-brain barrier.
  • Ovid and Graviton believe they have multiple selective and potent ROCK2 inhibitors that effectively penetrate the blood-brain barrier, which will be appropriate in future development indications.

Redx and Jounce Announce Recommended Business Combination

Retrieved on: 
Thursday, February 23, 2023
Immunotherapy, Therapy, News, Cancer, ROCK, Immune system, Fibrosis, US FDA, 2025, Drug discovery, Research, Patient, ROCK2, Date, Idiopathic pulmonary fibrosis, Tail, IPF, Alderley Park, AIM, Business analyst, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic diseases and the emerging area of cancer-associated fibrosis. Jounce is a clinical-stage immunotherapy company, dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker approach. The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points in the near and medium term.

Key Points: 
  • RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce
    Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025
    ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.
  • The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points in the near and medium term.
  • Named Redx Inc., the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX.
  • Led by current Redx CEO Lisa Anson, Dr Jane Griffiths current Redx Chair will become the non-executive Chair of the combined group; with the Board including representatives from both Redx and Jounce, in line with the relative shareholding percentages.

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

Retrieved on: 
Tuesday, August 23, 2022
Russell Midcap Index, Hang Seng Composite Index Series, Hong, Hang Seng Index, Safety, Research, Hang Seng China Enterprises Index, Pulmonary fibrosis, Sino Biopharmaceutical Limited, Interim, Board, Hepatitis, ROCK2, Respiratory system, Medullary thyroid cancer, Liver disease, Flurbiprofen, III, Thyroid cancer, Clinical trial, Forbes, Growth, Analgesic, Marketing, Patient, Board of directors, Fine chemical, Pharmaceutical industry, Pneumoconiosis, Group, PRC

-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.

Key Points: 
  • -- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.
  • During the Period, the Group recorded revenue of approximately RMB15.19 billion, an increase of approximately 5.9% against last year.
  • Sales of oncology medicines increased by 16.7% year-on-year to approximately 4.96 billion, accounting for approximately 32.6% of the Group's revenue.
  • Sino Biopharmaceutical Limited is a leading, innovative R&D-driven pharmaceutical conglomerate in the PRC.

Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value

Retrieved on: 
Monday, July 25, 2022
Newton, Sale, ROCK2, GLOBE, U.S. Securities and Exchange Commission, CYP11B2, Private Securities Litigation Reform Act, Fibrosis, Board, COVID-19, NASDAQ, Director, Oppenheimer, Board of directors, Security (finance), Therapy, Pharmaceutical industry

Angions Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the companys exclusive financial advisor to assist in this process.

Key Points: 
  • Angions Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the companys exclusive financial advisor to assist in this process.
  • Potential strategic options to be explored or evaluated as part of this process may include, but are not limited to, merger, reverse merger, other business combination, sale of assets, licensing, or other strategic transactions involving Angion.
  • Angion does not expect to disclose developments with respect to this process unless until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
  • Angions management and Board of Directors have moved quickly begin exploring strategic alternatives as the best option for enhancing and preserving shareholder value, stated Dr. Jay Venkatesan, Angions President and Chief Executive Officer.